-+ 0.00%
-+ 0.00%
-+ 0.00%

Atossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer

Benzinga·05/14/2025 12:19:03
Listen to the news

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile

SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer.